Search Results for: RASSF1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
FGFR4 fibroblast growth factor receptor 4
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • betaKlotho-mediated ligand binding
  • FGFR4 mutant receptor activation
  • FGFR4 ligand binding and activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR4
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR4 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Heparin
  • Ponatinib
  • Lenvatinib
  • Infigratinib
  • Erdafitinib
  • Pemigatinib
  • Futibatinib
FZR1 fizzy and cell division cycle 20 related 1
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of Emi1
  • Senescence-Associated Secretory Phenotype (SASP)
  • Assembly of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
GLIS2 GLIS family zinc finger 2
  • Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
GRM1 glutamate metabotropic receptor 1
  • G alpha (q) signalling events
  • Class C/3 (Metabotropic glutamate/pheromone receptors)
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Sensory perception of sweet, bitter, and umami (glutamate) taste
  • Glutamic acid
  • (S)-alpha-methyl-4-carboxyphenylglycine
HRAS HRas proto-oncogene, GTPase
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by RAS GAP mutants
  • Signaling by RAS GTPase mutants
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Ursolic acid
  • Penile cancer
  • Cervical cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Squamous cell carcinoma
  • Bladder cancer
IGFBP5 insulin like growth factor binding protein 5
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Post-translational protein phosphorylation
KAT2A lysine acetyltransferase 2A
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HATs acetylate histones
  • Notch-HLH transcription pathway
  • B-WICH complex positively regulates rRNA expression
  • Ub-specific processing proteases
  • RNA Polymerase I Transcription Initiation
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Cardiogenesis
  • Formation of WDR5-containing histone-modifying complexes
  • Formation of paraxial mesoderm
  • Coenzyme A
KCNE3 potassium voltage-gated channel subfamily E regulatory subunit 3
  • Phase 3 - rapid repolarisation
  • Phase 2 - plateau phase
  • Enflurane
  • Promethazine
  • Miconazole
  • Brugada syndrome (BRS)
KDELR2 KDEL endoplasmic reticulum protein retention receptor 2
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
KDM1A lysine demethylase 1A
  • HDACs deacetylate histones
  • HDMs demethylate histones
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
  • Regulation of PTEN gene transcription
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • Potential therapeutics for SARS
  • Negative Regulation of CDH1 Gene Transcription
  • Factors involved in megakaryocyte development and platelet production
  • Vafidemstat
LARS2 leucyl-tRNA synthetase 2, mitochondrial
  • Mitochondrial tRNA aminoacylation
  • Leucine
LATS2 large tumor suppressor kinase 2
  • Signaling by Hippo
MAP1B microtubule associated protein 1B
  • RSV-host interactions
MAP1S microtubule associated protein 1S
MAP2K3 mitogen-activated protein kinase kinase 3
  • Oxidative Stress Induced Senescence
  • activated TAK1 mediates p38 MAPK activation
  • Fostamatinib
  • Pimasertib
MAP2K6 mitogen-activated protein kinase kinase 6
  • NOD1/2 Signaling Pathway
  • Oxidative Stress Induced Senescence
  • activated TAK1 mediates p38 MAPK activation
  • Myogenesis
  • PI5P Regulates TP53 Acetylation
  • Interleukin-1 signaling
  • PKR-mediated signaling
  • Fostamatinib
  • Pimasertib
MAPK8 mitogen-activated protein kinase 8
  • Activation of BIM and translocation to mitochondria
  • Activation of BMF and translocation to mitochondria
  • NRAGE signals death through JNK
  • NRAGE signals death through JNK
  • NRIF signals cell death from the nucleus
  • Oxidative Stress Induced Senescence
  • FCERI mediated MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Activation of the AP-1 family of transcription factors
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-38 signaling
  • WNT5:FZD7-mediated leishmania damping
  • Signaling by ALK fusions and activated point mutants
  • Tamoxifen
  • Minocycline
  • Pyrazolanthrone
  • 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE
  • 2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE
  • N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE
  • 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE
  • 2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide
  • Halicin
MDM2 MDM2 proto-oncogene
  • AKT phosphorylates targets in the cytosol
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • Trafficking of AMPA receptors
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ub-specific processing proteases
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Methylation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Signaling by ALK fusions and activated point mutants
  • Degradation of CDH1
  • NPAS4 regulates expression of target genes
  • Zinc
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Penile cancer
  • Alveolar rhabdomyosarcoma
  • Choriocarcinoma
  • Osteosarcoma
  • Glioma
MET MET proto-oncogene, receptor tyrosine kinase
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D mediated inhibition of cell attachment and migration
  • RAF/MAP kinase cascade
  • MET Receptor Activation
  • Negative regulation of MET activity
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates RAS signaling
  • MET activates PI3K/AKT signaling
  • MET activates PTPN11
  • MET activates PTK2 signaling
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • MET interacts with TNS proteins
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • MET activates STAT3
  • MECP2 regulates neuronal receptors and channels
  • Drug-mediated inhibition of MET activation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Sunitinib
  • K-252a
  • SGX-523
  • 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
  • N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
  • 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
  • N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
  • 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
  • AMG-208
  • 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
  • Crizotinib
  • Cabozantinib
  • Capmatinib
  • Tivozanib
  • Fostamatinib
  • Tivantinib
  • Brigatinib
  • Amuvatinib
  • Tepotinib
  • Amivantamab
  • Cholangiocarcinoma
  • Gastric cancer
  • Renal cell carcinoma
MOAP1 modulator of apoptosis 1

Page 6 out of 8 pages